Xeris Biopharma Holdings, Inc. (XERS)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Financial Position (from SEC Filings)

$115.8M
Cash & Equivalents
$9.9M
Quarterly Burn Rate
$1,022M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (2 Assets)

DrugPhaseIndications
GLUCAGON
GVOKE PFS 		APPROVED —
DICHLORPHENAMIDE
DARANIDE 		APPROVED —

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for XERS.

SEC EDGAR Filings

All SEC filings for Xeris Biopharma Holdings, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.